我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

雷帕霉素替罗非班复合药物涂层支架预防支架内血栓和再狭窄的实验研究(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2007年第4期
页码:
384-387
栏目:
基础研究
出版日期:
2007-08-01

文章信息/Info

Title:
Experimental study of stentbased delivery of rapamycin and tirofiban on preventing instent thrombosis and restenosis
作者:
刁繁荣; 吕安林; 李军杰; 宋延彬; 温俊娜; 孟晓雪
第四军医大学西京医院心血管内科， 陕西 西安 710032
Author(s):
DIAO Fanrong;  L Anlin;  LI Junjie;  SONG Yanbin; WEN Junna; MENG Xiaoxue
Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi′an 710032, Shaanxi, China
关键词:
支架;  再狭窄;  雷帕霉素;  替罗非班
Keywords:
stent;  restenosis;  rapamycin;  tirofiban
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 探讨雷帕霉素替罗非班复合药物涂层支架预防支架内血栓和再狭窄的疗效及机制。方法 8只小型猪随机分为单纯雷帕霉素涂层支架(RES)组和雷帕霉素替罗非班复合药物涂层支架(RTES)组，每只动物于冠状动脉中置入支架2枚。术后RES组服用阿司匹林300 mg/d和氯吡格雷75 mg/d，3个月；RTES组服用阿司匹林300 mg/d，3个月，氯吡格雷75 mg/d，1个月。实验期间对动物行为学和出凝血障碍等并发症进行观察。3月后复查冠状动脉造影，处死动物，取出支架血管段，行组织病理学分析。结果 ①两组均未发现急性、亚急性和远期血栓，无出凝血等并发症发生。②支架部位血管腔面积: 雷帕霉素涂层支架组为(4.89±0.46)mm2,雷帕霉素替罗非班复合涂层支架组为(4.96±0.35)mm2；新生内膜面积:雷帕霉素涂层支架组为(1.05±0.09)mm2，雷帕霉素替罗非班复合涂层支架组为(1.12±0.10)mm2；管腔面积丢失率:雷帕霉素涂层支架组为（21±7）%，雷帕霉素替罗非班复合药物涂层支架组为（19±9）% 。结论 ①雷帕霉素替罗非班复合药物涂层支架可有效预防PCI术后支架内血栓形成。②雷帕霉素替罗非班复合药物涂层支架防治支架内再狭窄的疗效与单纯雷帕霉素支架无差异。
Abstract:
AIM To investigate the efficacy and the mechanism of stentbased rapamycin and tirofiban in combination (RTES) to prevent instent thrombosis and restenosis. METHODS 8 miniature pigs were randomly divided into experimental group and control group. Stents with rapamycintirofiban and polymer were implanted in the coronary arteries of pigs in the experimental group, while stents with rapamycin and polymer were implanted into the coronary arteries of pigs in the control group. Animals receiving RTES were treated with clopidogrel in a dose of 75 mg/d orally for 1 month after stent implantation, while Animals receiving RES in control group were treated orally with clopidogrel (75 mg/d) for three months. All animals were administered orally aspirin (300 mg/d) for 3 months. Coronary arteriographies were taken before, immediately after stents wrere implanted and before the pigs were sacrificed. Indexes of ethology and complication of hemorrhage were determined. Three momths later, arteries were compared in angiography, histopathology and histomorphometry analysis. RESULTS ①Acute ，subacute or later stent thrombosis weren′t observed in both groups, as well as complications of hemorrhage and blood coagulation. ②The lumen areas of the experimental group were similar with those of the control group ［(4.96±0.35） vs （4.89±0.46）mm2］. The neointlmal areas in the experimental group were similar with those in the control group ［(1.12±0.10） vs （1.05±0.09）mm2］. Both type of stents had similar effect on lumen stenosis rates (19%±9% vs 21%±7%). The side effects were not found in experiment animals. CONCLUSION ①The rapamycin tirofiban eluting stent can prevent instent thrombosis effectively after PCI. ②The efficacy of the rapamycin tirofiban eluting stent in preventing instent restenosis is not significantly different with the rapamycin eluting stent.

参考文献/References

［1］ Grech ED. ABC of interventional cardiology: Percutaneous coronary intervention. I: history and development［J］. BMJ,2003,326（7398）:1080-1082.

［2］ Morice MC, Serruys PW, Sousa JE,et al. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization［J］. N Engl J Med， 2002,346（23）:1773-1780.

［3］ Nakatani M, Takeyama Y, Shibata M, et al. Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting［J］. Cardiovasc Pathol, 2003,12（1）:40-48.

［4］ Drachman DE,Simon DI. Inflammation as a mechanism and therapeutic target for instent restenosis［J］. Curr Atheroscler Rep，2005，7(1):44-49.

［5］ Lemos PA, Serruys PW, Sousa JE. Drugeluting stents: cost versus clinical benefit［J］. Circulation, 2003,107(24):3003-3007.

［6］ 李慧丽,万锕俊,王彬尧,等. 药物涂层支架的研究进展［J］.心脏杂志,2004,16（5）:476-479.

［7］ Kereiakes DJ. Hippocrates revisited: the evidence for drugeluting stents［J］. Circulation,2003,107（24）:3012-3014.

［8］ Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimuseluting stent: should we be cautious? ［J］. Circulation, 2004,109(6):701-705.

［9］ 张莉莉，贾国良，王海昌，等. 抗血小板药物对冠心病支架置入术后再狭窄防治效果的观察［J］.心脏杂志,2004,16(5):459-461.

［10］Gaciong Z.［Clopidogrel and aspirin versus aspirin alone in prevention of atherothrombotic events. The results of CHARISMA study］［J］. Kardiol Pol， 2006，64(5):548-551,discussion， 551-552.

［11］Heitzer T,Ollmann I,Koke K,et al.Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease［J］.Circulation,2003,108(5):536-541.Epub 2003 Jul 21.

［12］Ercan E,Bozdemir H,Tengiz I,et al.Decreased soluble cell adhesion molecules after tirofiban infusion in patients with unstable angina pectoris［J］.Thromb J,2004,2(1):4.

备注/Memo

备注/Memo:
收稿日期：2006-12-06.通讯作者：吕安林，副主任医师，主要从事冠心病介入治疗研究Email:lvanlin@fmmu.edu.cn 作者简介：刁繁荣，主治医师，硕士生Email:anan0521@163.com
更新日期/Last Update: